ReutersAlabama lawmakers passed a bill on Thursday that would criminalize gender-affirming healthcare for transgender youth, with a threat of 10 years in prison for medical providers.
For years, you’ve been replacing your patient’s testosterone. Maybe it’s time to consider replacing how it’s delivered. While there have been frequent, and prominent, new products developed for treating hypogonadism […]
Myovant announced that the company’s Phase III HERO trial relugolix met the study’s primary endpoint and six key secondary endpoints in advanced prostate cancer.
The U.S. Food and Drug Administration declined to approve Lipocine Inc.’s oral drug to treat a condition that results in lower production of male sex hormone for the third time, sending the drug developer’s shares down 34 percent.
Phase 3 ARCHES Trial Shows Xtandi Significantly Improved Radiographic Progression-Free Survival in Men with mHSPC
Androgen Deprivation Therapy (ADT), Clinical Data, Clinical Trials, CYP2C8 inhibitors, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), R&D, TestosteronePfizer Inc. and Astellas Pharma Inc. announced results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).
